Fig. 6: Patient survival outcomes improve for MSLN high MSS CRC when treated with pembrolizumab and ICI. | Cancer Gene Therapy

Fig. 6: Patient survival outcomes improve for MSLN high MSS CRC when treated with pembrolizumab and ICI.

From: Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer

Fig. 6

Patient insurance claims data provided to Caris Life Sciences were used to generate Kaplan–Meier curves via the CODEai™ data portal. Curves depict survival from the time of tissue collection or first treatment to last contact for the entire cohort (A) and MSS cohort (B) of CRC patients with MSLN low (blue/cohort 1) compared to MSLN high (red/cohort 2) across several therapeutic interventions.

Back to article page